The ECFS welcomes the approval of Vertex’s KALYDECO (ivacaftor) by the FDA.
Press release available here (external site)
Update from May 25, 2012
Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis. Further information in the Press Release here.